HUTCHMED will present the full SAFFRON lung cancer data in a Presidential Symposium at ESMO 2026 in Madrid on Sunday 25 October, the first detailed look at results that already underpin a US regulatory filing.
HUTCHMED (China) Limited (LSE:HCM), the oncology and immunology group quoted on AIM, Nasdaq and the Hong Kong Stock Exchange, is due to unveil detailed data from its SAFFRON global Phase III trial on Sunday 25 October 2026. According to the company's "Data to be Presented at ESMO 2026" announcement of 24 September 2026, SAFFRON (abstract LBA6) has been selected for Presidential Symposium II at the ESMO Congress, running from 16:30 to 18:15 CEST, with Shun Lu as presenter. The congress takes place in Madrid from 23–27 October 2026.
Why does ESMO matter? So far, HUTCHMED has only said that SAFFRON met its progression-free survival (PFS) endpoint and showed a significant improvement in overall survival (OS) versus chemotherapy; no figures have been disclosed. That headline result already supports a US New Drug Application (NDA) submitted by partner AstraZeneca on 29 September 2026. The ESMO presentation should therefore be the first opportunity to see the size of the benefit. There has been no new announcement in October, but HUTCHMED is one of the stocks drawing heavy discussion among UK investors today as the congress approaches.
The ESMO 2026 line-up
The 24 September announcement sets out HUTCHMED's schedule in Madrid:
- Surufatinib combination in extrapulmonary NEC (2394RO): Rapid Oral session, Friday 23 October 2026, 16:15–17:45 CEST.
- SAFFRON (LBA6): Presidential Symposium II, Sunday 25 October 2026, 16:30–18:15 CEST, presented by Shun Lu.
- SANOVO (LBA69): Proffered Paper session, Monday 26 October 2026, 08:30–10:00 CEST, presented by Yi-Long Wu.
SANOVO, a late-breaking abstract, is the second key readout. Both trials test the same combination of savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®), but in different settings.
What SAFFRON and SANOVO have shown so far
SAFFRON is a global Phase III study of ORPATHYS® plus TAGRISSO® in patients with EGFR-mutated non-small cell lung cancer (NSCLC) with MET overexpression or amplification, whose disease has progressed after EGFR tyrosine kinase inhibitor (TKI) therapy. HUTCHMED announced on 17 August 2026 that the trial met its PFS endpoint and showed a significant OS improvement versus chemotherapy, without giving numbers.
SANOVO is a Phase III study in China involving 326 patients with first-line EGFR-mutated, MET-overexpressed NSCLC. On 1 September 2026, the company said it had met its primary PFS endpoint. Again, no hazard ratios or medians were disclosed.
The ESMO presentations will therefore move both studies from qualitative headlines to quantified results. That matters for how clinicians, regulators and partners may assess the combination.
The US filing and the GSK deal
On 29 September 2026, HUTCHMED announced that AstraZeneca had submitted an NDA to the US Food and Drug Administration for savolitinib 300 mg twice daily plus osimertinib 80 mg once daily in the SAFFRON patient population. The filing is based on SAFFRON, which enrolled 338 patients across 230 centres in 29 countries. No PDUFA date or milestone payment was disclosed.
Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer, said: "This filing is an important step toward potentially bringing ORPATHYS® plus TAGRISSO® to patients in the US".
Earlier, on 3 September 2026, HUTCHMED licensed HMPL-A830, a KRAS-EGFR antibody-targeted therapy conjugate (ATTC), to GSK for worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan. The terms comprise US$110 million upfront at closing, up to US$1.185 billion in milestones and tiered royalties, for a total of up to US$1.295 billion. Closing remains subject to customary conditions, including antitrust reviews, and no date has been given. Johnny Cheng said: "We are proud to work with GSK, a globally leading biopharmaceutical company". Dr Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D at GSK, said: "The dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care."
HUTCHMED (LSE:HCM) has also started a global Phase Ia dose-escalation trial of HMPL-A830 (NCT07718581), with the first patient dosed in China on 24 September 2026. Separately, on 28 August 2026, China's NMPA granted conditional approval for ATLED® (fanregratinib) in FGFR2 fusion/rearrangement intrahepatic cholangiocarcinoma, based on an IRC-assessed objective response rate of 42.5%.
The business and its finances
HUTCHMED describes itself as a commercial-stage oncology and immunology company focused on China and global markets. Its marketed or approved medicines include ORPATHYS® (savolitinib, partnered with AstraZeneca), ATLED® (fanregratinib), fruquintinib (ELUNATE®/FRUZAQLA®) and surufatinib. Non-executive Chairman Dr Dan Eldar said in the interim results that "HUTCHMED has a clear strategic focus: to build a globally competitive oncology portfolio".
Key figures from the interim results for the six months to 30 June 2026, published on 30 July 2026:
- Total revenue of $278.3 million (H1 2025: $277.7 million).
- Oncology/Immunology consolidated revenue of $162.3 million (H1 2025: $143.5 million).
- Net income attributable of $15.9 million (H1 2025: $455.0 million, which included a divestment gain).
- Cash, cash equivalents and short-term investments of $1,374.8 million.
- Bank borrowings of $94.5 million.
The company reiterated FY2026 guidance for Oncology/Immunology consolidated revenue of $330 million to $450 million. The US$110 million GSK upfront payment is due at closing, which is still pending.
Risks to weigh
Several risks are visible in HUTCHMED's own announcements:
- Regulatory: the US NDA is under FDA review with no decision date disclosed. ATLED® has conditional approval only, and a confirmatory Phase IIIb study is required.
- Deal execution: the GSK licence is subject to closing conditions, including antitrust reviews.
- Management: Chief Executive Officer Dr Weiguo Su is on a leave of absence, with Johnny Cheng serving as Acting CEO.
- Data disclosure: neither SAFFRON nor SANOVO has published figures yet, so the ESMO data may or may not match expectations built on the headline announcements.
There is also some uncertainty around the share price. Market data displayed a headline price of 216.00p on 15 October, but the trades listed that day were between 204.60p and 211.37p, so the true day move is unclear. Over the past 52 weeks the shares have traded between 153.00p and 239.00p, and market data showed a market capitalisation of £1.88b on 869.07m shares.
What to watch next
The congress itself is the main near-term event. Investors are likely to focus on the PFS and OS figures for SAFFRON on 25 October, followed by the SANOVO data on 26 October. Beyond ESMO, the key items are any FDA acceptance or review timetable for the NDA, the closing of the GSK transaction and receipt of the US$110 million upfront payment, and progress against the reiterated revenue guidance.
HUTCHMED enters ESMO 2026 with a US filing in place, a significant licensing deal awaiting closing and a substantial cash position. What it has not yet provided is the detail behind its SAFFRON and SANOVO lung cancer readouts. The Presidential Symposium on 25 October is when that detail is due, and the numbers presented will shape how the market judges both the SAFFRON filing and the broader savolitinib programme.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...